CPRX Financial Facts
Total operating costs and expenses: 3.91MProvision for income taxes: 0
See Full Income Statement
Deficit accumulated during the development stage: -103.98M
Accounts payable: 1.06M
See Full Balance Sheet
Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings
|
Expand Research on CPRX
| Next EPS Date | 8/12/26 | EPS Growth Rate | -30.9% |
|---|---|---|---|
| Average EPS % Beat Rate | +99.9% | Revenue Growth Rate | +5.9% |
| Average % Move 1-Wk after EPS | -0.5% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/12/26  |
Q226 | N/A | $0.47 | N/A | N/A | $155.2M | = | N/A | N/A | ||
| 5/13/26 |
Q126 | N/A | $0.44 | N/A | N/A | $147.25M | = | N/A | N/A | ||
| 2/25/26 | Q425 | $0.68 | $0.31 | +$0.37 | $152.6M | $141.49M | = |  | | Details | |
| 11/5/25 | Q325 | $0.68 | $0.33 | +$0.35 | $148.4M | $136.37M | = | | | Details | |
| 8/6/25 | Q225 | $0.68 | $0.39 | +$0.29 | $146.54M | $140.22M | = | | | Details | |
| 5/7/25 | Q125 | $0.68 | $0.34 | +$0.34 | $141.4M | $131.54M | = | | | Details | |
| 2/26/25 | Q424 | $0.70 | $0.32 | +$0.38 | $141.8M | $133.68M | = | | | Details | |
| 11/6/24 | Q324 | $0.57 | $0.30 | +$0.27 | $128.7M | $123.41M | = | | | Details |
